The CM-Path Biobanking Sample Quality Improvement Tool: A Guide for Improving the Quality of Tissue Collections for Biomedical Research and Clinical Trials in Cancer

Valerie Speirs*, Harriet Foden, Jane Hair, Raffaella Tate, Helen Pitman, Karin Oien, Andrew Hall, Gareth Thomas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)


Biobanking is now a key discipline in cancer research and its infrastructure. This helps accelerate translational research and is typically pathology-led. To use biobanked tissues to best effect, sample quality is paramount, and biobanks have a responsibility to ensure this is achieved. In 2016, the National Cancer Research Institute (NCRI) established the Cellular & Molecular Pathology initiative (CM-Path), which aims to re-invigorate UK academic pathology in the UK. One of the goals of the CM-Path biobanking subgroup group was to create a Biobanking Sample Quality Improvement Tool. The tool is a confidential self-assessment of current practices within a biobank, focusing on tissue quality and identifying areas with the potential for improvement. Here we describe the development and implementation of this tool and discuss what it can offer to the cancer biobanking community.
Original languageEnglish
JournalBiopreservation and Biobanking
Publication statusAccepted/In press - 13 May 2020

Bibliographical note

Funding: The NCRI's CM-Path initiative was established in 2016 with the aim of re-invigorating academic pathology. It is funded as a collaborative venture between ten of the NCRI partner organisations: Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief Scientist Office (Scotland), the Department of Health and Social Care (England), Health and Care Research Wales, Health and Social Care (Northern Ireland), the Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care. These organisations did not participate in study design; collection, analysis and interpretation of data; writing the report or the decision to submit the paper for publication.

Thanks to the following for assisting in the scoping exercise: Joanna Baxter, Cambridge Blood and Stem Cell Bank; Chris Birkett, Human Tissue Authority; Tim Brend, Breast Cancer Now Tissue Bank, University of Leeds; Brian Clark, Novo Nordisk; Emma Lawrence, UKCRC Tissue Directory and Coordination Centre; Alex MacLellan, CRUK Tissue Group, Edinburgh; Balwir Matharoo-Ball, Nottingham Health Sciences Biobank; Bill Mathieson, NHS Grampian Biorepository; Gita Mistry Children’s Cancer and Leukaemia Group Tissue Bank; Will Navaie, Health Research Authority; Rob Oliver, Salford Royal NHS Foundation Trust; Kathleen Potter, Cancer Sciences Tissue Bank, University of Southampton; Doris Rassl, Papworth Hospital NHS Foundation Trust; Jane Steele, Human Biomaterials Resource Centre, University of Birmingham; Sarah Yeats, WISH Lab, University of Southampton. Special thanks Anne Carter for her tireless work with CCB and to staff at the following biobanks who piloted the Sample Quality Improvement Tool: Greater Glasgow & Clyde Biorepository, Leeds Breast Cancer Now Tissue Bank, Leeds Multidisciplinary Research Tissue Bank and Southampton Tissue Bank.


Dive into the research topics of 'The CM-Path Biobanking Sample Quality Improvement Tool: A Guide for Improving the Quality of Tissue Collections for Biomedical Research and Clinical Trials in Cancer'. Together they form a unique fingerprint.

Cite this